# US 2013/0157290 A1 · Soluble st2 as a marker for disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157290 A1
- Document ID: US20130157290A1
- Status: Published application
- Kind: A1
- Application number: 13/328,406
- Filed: 2011-12-16
- Published: 2013-06-20
- Earliest claimed: 2011-12-16
- Inventors: Yves Levy
- Web page: https://patentgrep.com/patent/US20130157290A1

## CPC

- G01N 33/6866: {Interferon}
- G01N 33/6869: {Interleukin}
- G01N 2333/7155: for interleukins [IL]
- G01N 2800/32: Cardiovascular disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.

## Claims

### Claim 1

A method of predicting the risk of mortality of a HIV-infected subject comprising
(i) determining the level of sST2 in a biological sample from said subject; and
(ii) comparing said level of ST2 with a control level
wherein a level of sST2 in the subject sample which is higher than that of the control is indicative of an increased risk of mortality.

### Claim 2 (depends on 1)

The method of claim 1, wherein the risk of mortality is risk of death following a cardiovascular event.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has pre-existing cardiovascular disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has no pre-existing cardiovascular disease.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has not yet commenced anti-HIV therapy.

### Claim 6 (depends on 3)

The method of claim 3, wherein the control level is derived from HIV-infected subjects with pre-existing cardiovascular disease.

### Claim 7 (depends on 4)

The method of claim 4, wherein the control level is derived from HIV-infected subjects with no pre-existing cardiovascular disease.

### Claim 8 (depends on 1)

The method of claim 1, wherein the risk of mortality is risk of death within one year.

### Claim 9 (depends on 1)

The method of claim 1, wherein the biological sample is whole blood, plasma or serum.

### Claim 10

A method of prognosis of cardiovascular disease in an HIV-infected subject, said method comprising:
(i) determining the level of sST2 in a biological sample from said subject; and
(ii) comparing said level of sST2 with a control level;
wherein a level of sST2 in the subject sample which is higher than that of the control is indicative of a poor prognosis.

### Claim 11 (depends on 1)

The method of claim 1, said method further comprising the step of selecting a suitable treatment based on the expression of sST2 in the subject sample compared to the control.

### Claim 12 (depends on 1)

The method of claim 1, wherein an aggressive treatment is selected where an elevated level of sST2 is detected in the subject sample compared to the control.

### Claim 13

A method of monitoring the efficacy of treatment of a cardiovascular disease, said method comprising monitoring sST2 expression during the course of the treatment, wherein a reduction in sST2 level over the course of the treatment is indicative of the efficacy of the treatment.
